Desensitization protocol for rituximab-induced serum sickness

Current Drug Safety

Volumn 9, Issue 3, 2014, Pages 240-242

  Fajt, Merritt L ^a   Petrov, Andrej A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Desensitization; Hypersensitivity; Mucosa associated lymphoid tissue; Rituximab; Serum sickness

Indexed keywords

DIPHENHYDRAMINE; FAMOTIDINE; FEXOFENADINE; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB;

ABDOMINAL DISCOMFORT; ADULT; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; CASE REPORT; COLONOSCOPY; DESENSITIZATION; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; FAMILY HISTORY; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INTENSIVE CARE UNIT; LYMPHOID TISSUE; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NOSE OBSTRUCTION; PRIORITY JOURNAL; SERUM SICKNESS; SJOEGREN SYNDROME; SMOKING; STOMACH MUCOSA; THYROID CARCINOMA;

EID: 84923375957     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574886309666140509154056     Document Type: Article

References (20)

1. [1] Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachmann PJ, eds. Clinical Aspects of Immunology. Oxford: Blackwells, 1975: 761-81.
2. Baldo BA. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity response. Oncoimmunology 2013; 2(10): e26333.
3. [3] Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol 2007; 34(2): 430.
4. [4] Schutgens RE. Rituximab-induced serum sickness. Br J Haematol 2006; 135(2): 147.
5. [5] Rituxan®[package insert]. San Francisco, CA: Genetech, Inc; 2013. Available at http://www.gene.com/download/pdf/rituxan_prescribing. pdf
6. [6] Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther 2005; 7(Suppl 3): S19-25.
7. Arredondo-Garza T, Majluf-Cruz A, Vela-Ojeda J, et al. Peri-Infusional Adverse Reactions to Rituximab in Patients with Non-Hodgkin's Lymphoma. Arch Med Res 2013; 44(7): 549-54.
8. [8] Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14(12): 1792.
9. [9] Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13(2): 94-5.
10. Goto S, Goto H, Tanoshima R, et al. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 2009; 89(3): 305-9.
11. DeMonaco NA, Jacobs SA. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. Clin Nucl Med 2007; 32(12): 933-4.
12. Disperati P, Hicks LK, Buckstein R. Rituximab-induced serum sickness in a patient with follicular lymphoma. Leuk Lymphoma 2007; 48(8): 1633-5.
13. [13] Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J 2006; 12(1): 3.
14. [14] Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 2013; 68(7): 853-61.
15. [15] Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012; 61(9): 1575-84.
16. Matsui T, Hidaka M, Kawakita T, et al. Serum sickness induced by rituximab infusion; report of two cases with hematological malignancies. Rinsho Ketsueki 2009; 50(4): 304-8.
17. [17] Çelik G, Pichler W, Adkinson NF. Drug Allergy. In: Adkinson NF, Bochner BS, Burks AW, Busse WW, Holgate ST, Lemanske RF, O'Hehir RE, eds. Middleton’s Allergy: Principles and Practice, 8th ed. Philadelphia, PA: Elsevier Inc. (Saunders); 2014: 1274-1295.
18. Liu A, Fanning L, Chong H, et al. Desensitization regimens for drug allergy: state of the art in the 21st century. Clin Exp Allergy 2011; 41(12): 1679-89.
19. [19] Shalit M, Levi-Schaffer F. Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy 1995; 25(9): 896-902.
20. [20] Kepley CL. Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol 2005; 138(1): 29-39.